LynxCare's comprehensive data assets* offer fresh insights into Immuno-Oncology, Breast Cancer, Lung Cancer, Chronic Lymphocytic Leukemia (CLL), and Multiple Myeloma (MM), including comorbidity factors, treatment patterns, and staging.
Our granular and quality controlled real-world datasets can unlock invaluable insights into the treatment and prognosis of various cancer types, empowering clinicians to make informed decisions. Through our federated real-world dataset, we can equally help life sciences close evidence gaps throughout the product lifecycle, from development to launch and growth.
Click below and discover our Immuno-Oncology, Breast Cancer, Lung Cancer, Chronic Lymphocytic Leukemia (CLL), and Multiple Myeloma (MM) dataset insights.
Quality Control and Data Freshness
We adhere to strict data quality standards to ensure the accuracy and reliability of our data. Our team of experts verifies and validates data from intake, data processing up till analytics, ensuring consistency and completeness throughout the patient pathway. Each statistic needs to be validated by the individual hospital before delivery.
Our data is updated regularly to ensure we provide insights based on the latest and most accurate information. Leveraging our HL7-based gateway, our datasets remain fresh with a max of 6-months delay.
OMOP CDM Data Warehouse
Our data is stored in the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM), enabling easy access and integration with other healthcare or research IT solutions. With our well-structured and standardized data storage, our clients can start analyzing the data immediately and efficiently.
The Future of Cancer Treatments
How LynxCare Can Help
With our comprehensive dataset and world-class expertise, LynxCare is well-positioned to help clinicians tailor treatments to specific patient needs, opening up the possibility of personalized medicine. Our data asset provides valuable insights into individual pathways of cancer patients, enabling clinicians to make more informed treatment decisions.
Our data asset aims to ultimately improve patient outcomes by providing insights into the clinical pathway of cancer patients. By analyzing real-world patient data, our dataset offers a unique perspective on the
effectiveness and safety of different treatments. This information can help clinicians make more informed treatment decisions, leading to better outcomes for patients.
LynxCare is committed to driving innovation in cancer treatment and management. With our world-class expertise in data analysis and interpretation, we aim to continue to provide valuable insights and solutions to healthcare providers and researchers. Our comprehensive dataset offers a wealth of information for life science companies and other stakeholders interested in advancing cancer therapy.
* LynxCare datasets concern datasets within the LynxCare's European hospital network. The hospitals are the data controllers. No commitment before site approval on RWE request.